Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Advanced Oncotherapy's Enterprise Value is €78.70 Mil.
Advanced Oncotherapy's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was €-31.52 Mil. Therefore, Advanced Oncotherapy's EV-to-EBIT ratio for today is -2.50.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Advanced Oncotherapy's Enterprise Value is €78.70 Mil.
Advanced Oncotherapy's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was €-28.59 Mil. Therefore, Advanced Oncotherapy's EV-to-EBITDA ratio for today is -2.75.
Advanced Oncotherapy Enterprise Value Historical Data
The historical data trend for Advanced Oncotherapy's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Advanced Oncotherapy's Enterprise Value
For the Medical Devices subindustry, Advanced Oncotherapy's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Oncotherapy's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Advanced Oncotherapy's Enterprise Value falls into.
Advanced Oncotherapy Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Advanced Oncotherapy's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Oncotherapy (FRA:R3I1) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Advanced Oncotherapy's current Enterprise Value is €78.70 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was €-31.52 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Advanced Oncotherapy's current Enterprise Value is €78.70 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was €-28.59 Mil.
Advanced Oncotherapy's current Enterprise Value is €78.70 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Oncotherapy Enterprise Value Related Terms
Thank you for viewing the detailed overview of Advanced Oncotherapy's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Advanced Oncotherapy (FRA:R3I1) Business Description
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:R3I1 has been successfully added to your 